UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

  

 

Date of Report (Date of earliest event reported) December 8, 2015

 

 

 

 Kewaunee Scientific Corporation

 

(Exact name of registrant as specified in its charter)

 

     
Delaware 0-5286 38-0715562
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
       

 

2700 West Front Street

Statesville, North Carolina

(Address of principal executive offices)

 

 

28677

(Zip Code)

 

 

Registrant’s telephone number, including area code 704-873-7202

 

 

 

N/A 

(Former name or former address, if changed since last report.)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 2.02Results of Operations and Financial Condition

 

On December 8, 2015, Kewaunee Scientific Corporation issued a press release announcing its financial results for the second quarter ended October 31, 2015. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

  

Item 9.01Financial Statements and Exhibits

 

  (d)Exhibits:

 

Exhibit No.  
99.1 Press Release of Kewaunee Scientific Corporation dated December 8, 2015

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    (Registrant)  
       Kewaunee Scientific Corporation  
         
Date:  December 8, 2015      /s/ Thomas D. Hull III  
     

Thomas D. Hull III

Vice President, Finance

 
      Chief Financial Officer  

 

 



Kewaunee Scientific Reports Results for Second Quarter

STATESVILLE, N.C., Dec. 8, 2015 /PRNewswire/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported results for its second quarter ended October 31, 2015.

Sales for the quarter were $31,037,000, a 2.6% increase from sales of $30,258,000 in the prior year. Domestic sales for the quarter were $26,279,000, up 11.2% from sales of $23,629,000 in the second quarter of last year. International sales for the quarter were $4,758,000, down 28.2% from sales of $6,629,000 in the second quarter last year.

Net earnings for the quarter were $695,000, or $0.26 per diluted share, as compared to net earnings of $1,202,000, or $0.45 per diluted share, in the second quarter last year. Earnings for the quarter were lower in comparison as a result of particularly strong International sales due to the timing of a shipment of a large order during the second quarter of last year. Earnings were also unfavorably impacted by non-recurring costs related to the retirement of a key executive.

The order backlog was $92.4 million at October 31, 2015, as compared to $84.5 million at October 31, 2014, and $86.7 million at July 31, 2015. Incoming orders for the Domestic business were strong during the quarter, as opportunities increased from the improving marketplace for laboratory furniture and scientific equipment in the United States. The Company continues to see and pursue new opportunities in the International markets, although the timing of international incoming orders continues its unevenness from quarter-to-quarter.

The Company's balance sheet and financial condition remain strong. Unrestricted cash on hand was $3.3 million at the end of the quarter, as compared to $4.9 million at the end of the second quarter last year. Working capital was $29.0 million, as compared to $27.9 million at the end of the second quarter last year. Short-term debt and interest rate swaps were $5.5 million at the end of the quarter, as compared to $0.9 million at the end of the second quarter last year, and total bank borrowings and interest rate swaps were $9.5 million, as compared to $5.3 million at the end of the second quarter last year.

"Improving conditions in the Domestic marketplace resulted in strong incoming orders for the quarter," said David M. Rausch, Kewaunee's President and Chief Executive Officer. "For our International business, a large order shipped in the second quarter of last year adversely affected the year-over-year comparison with this quarter; however, our expanded sales organization and continued strengthening of the Kewaunee brand worldwide enable us to take advantage of numerous International opportunities where we are involved in the design and quote process."

"Looking forward, I remain optimistic we will continue to experience sales growth in fiscal year 2016. Going forward, I expect earnings to continue to improve through the balance of the fiscal year as we focus on improving our productivity and delivering cost reductions. We expect the domestic laboratory casework marketplace will continue to be strong with improved demand for both new construction and renovation projects. My optimism is also based on our strong order backlog and expectations that our International business will continue its long-term progress."

About Kewaunee Scientific
Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Products include steel, wood, and laminate casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin worksurfaces and sinks.

The Company's corporate headquarters is located in Statesville, North Carolina. Direct sales offices are located in the United States, India, Singapore, and China. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company's China headquarters, sales office, and assembly operation are located in Suzhou Industrial Park, China. Kewaunee Scientific's website is located at http://www.kewaunee.com.

This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning these factors is contained in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:   

Thomas D. Hull III


(704) 871-3290

Kewaunee Scientific Corporation

Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)














Three months ended


Six months ended




 October 31,


October 31,




2015


2014


2015


2014

Net sales



$    31,037


$    30,258


$    62,126


$    60,792

Cost of products sold


25,505


24,436


50,751


48,822

Gross profit



5,532


5,822


11,375


11,970

Operating expenses


4,403


3,950


8,722


8,298

Operating earnings


1,129


1,872


2,653


3,672

Other income


85


125


187


251

Interest expense


(61)


(102)


(153)


(183)

Earnings before income taxes


1,153


1,895


2,687


3,740

Income tax expense


446


667


1,017


1,252

Net earnings



707


1,228


1,670


2,488

Less: net earnings attributable to









    the noncontrolling interest


12


26


35


52

Net earnings attributable to 









    Kewaunee Scientific Corporation


$         695


$      1,202


$      1,635


$      2,436











Net earnings per share attributable to









    Kewaunee Scientific Corporation stockholders







       Basic



$        0.26


$        0.46


$        0.62


$        0.93

       Diluted



$        0.26


$        0.45


$        0.61


$        0.92











Weighted average number of common









shares outstanding









       Basic



2,671


2,626


2,650


2,623

       Diluted



2,690


2,659


2,674


2,655






















Kewaunee Scientific Corporation




Condensed Consolidated Balance Sheets




(in thousands)


















October 31,


April 30,








2015


2015



Assets





(Unaudited)





Cash and cash equivalents




$      3,274


$      3,044



Restricted Cash




1,679


2,276



Receivables, less allowances




28,572


29,106



Inventories





13,740


12,745



Prepaid expenses and other current assets




2,142


1,591



    Total Current Assets




49,407


48,762



Net property, plant and equipment




14,557


14,523



Other assets





6,234


6,205



Total Assets





$    70,198


$    69,490













Liabilities and Equity









Short-term borrowings and interest rate swaps




$      5,529


$      4,955



Current portion of long-term debt




421


421



Accounts payable




9,654


11,232



Other current liabilities




4,797


4,447



    Total Current Liabilities




20,401


21,055



Other non-current liabilities




13,325


13,236



    Total Liabilities




33,726


34,291



Noncontrolling interest




274


323



Kewaunee Scientific Corporation equity




36,198


34,876



    Total Equity




36,472


35,199



Total Liabilities and Equity




$    70,198


$    69,490















Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Kewaunee Scientific Charts.
Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Kewaunee Scientific Charts.